Axelopran clinical trials
Also written TD-1211.
How each study uses axelopran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the axelopran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
10 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 2
Glycyx Therapeutics (8) · John Kirkwood (1) · HealthPartners Institute (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test axelopran.
- Aug 2027A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck CancerPhase 1/2 · Glycyx Therapeutics
- Nov 2027Axelopran for Advanced Cancer in Patients Receiving OpioidsPhase 2 · HealthPartners Institute
Studies
Open first, then newest update. How each study uses axelopran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Axelopran and Nivolumab in PD-1-Refractory Metastatic MelanomaRecruitingPhase 1/2John KirkwoodNCT07631325Written as Axelopran
- A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck CancerNot yet recruitingPhase 1/2Glycyx TherapeuticsNCT07662720Written as axelopran
- Axelopran for Advanced Cancer in Patients Receiving OpioidsRecruitingPhase 2HealthPartners InstituteNCT07354919Written as axelopran
- TD-1211 IV/Oral Mass Balance StudyCompletedPhase 1Glycyx TherapeuticsNCT01702194Written as TD-1211 IV [C14]
- A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced ConstipationCompletedPhase 2Glycyx TherapeuticsNCT01459926Written as TD-1211
- A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced ConstipationCompletedPhase 2Glycyx TherapeuticsNCT01333540Written as TD-1211
- A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced ConstipationCompletedPhase 1/2Glycyx TherapeuticsNCT01040637Written as TD-1211
- A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)CompletedPhase 2Glycyx TherapeuticsNCT01401985Written as TD-1211
- A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211CompletedPhase 1Glycyx TherapeuticsNCT01568411Written as TD-1211
- TD-1211 Single-Dose Study in Elderly and Young Healthy SubjectsCompletedPhase 1Glycyx TherapeuticsNCT01655771Written as TD-1211 Dose 1
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Axelopran and Nivolumab in PD-1-Refractory Metastatic MelanomaOct 19, 2026NCT07631325
Codes
What other systems call axelopran · ClinicalTrials.gg INT006400
- UNII (FDA) 85U7ROB149AXELOPRANConfirmed FDA, Wikidata
- Wikidata Q20707800axelopranConfirmed FDA, Wikidata
- NCI Thesaurus C171856AxelopranOne source FDA
- DrugBank DB12013One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 85U7ROB149 | AXELOPRAN | Confirmed FDA, Wikidata |
| Wikidata | Q20707800 | axelopran | Confirmed FDA, Wikidata |
| NCI Thesaurus | C171856 | Axelopran | One source FDA |
| DrugBank | DB12013 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.